Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

Clinica Chimica Acta

Volumn 373, Issue 1-2, 2006, Pages 99-103

  Zhang, Wei ^a   Yu, Bang Ning ^a   He, Yi Jing ^a   Fan, Lan ^a   Li, Qing ^a   Liu, Zhao Qian ^a   Wang, An ^a   Liu, Ya Li ^a   Tan, Zhi Rong ^a   Fen Jiang, ^a   Huang, Yuan Fei ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

421C>A; BCRP; Pharmacokinetics; Polymorphism; Rosuvastatin

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C9; ORGANIC ANION TRANSPORTER 2; ROSUVASTATIN;

ALLELE; AREA UNDER THE CURVE; ARTICLE; ASIAN; BLOOD LEVEL; CONTROLLED STUDY; GENE; GENE MUTATION; GENOTYPE; HOMOZYGOTE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUNTEER; WILD TYPE;

ADMINISTRATION, ORAL; ATP-BINDING CASSETTE TRANSPORTERS; CHINA; FLUOROBENZENES; GENETIC SCREENING; GENETIC TESTING; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; REFERENCE VALUES; SULFONAMIDES;

EID: 33747884712     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.05.010     Document Type: Article

References (20)

1. Christopher I., and Carswell G.L. Plosker and Blair Jarvis. Rosuvastatin. Drugs 62 (2002) 2075-2085
2. Brown C.D.A., Windass A., Bleasby K., and Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [Abstract]. Atherosclerosis 2 (2001) 90
3. Nezask K., Higaki K., Takeuchi M., Nakano M., and Koike M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33 (2003) 379-388
4. McCormick A.D., McKillop D., Butters C.J., Milles G.S., Baba T., Touchi A., et al. ZD4522-an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 40 (2000) 1055.5
5. Martin P.D., Warwick M.J., Dane A.L., Hill S.J., Giles P.B., Philips P.J., et al. Metabolism, excretion and pharmacokinetics of rosuvastatin. Clin Ther 25 (2003) 2822-2835
6. Zamber C.P., Lamba J.K., Yasuda K., Farnum J., Thummel K., Schuetz J.D., et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13 (2003) 19-28
7. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., and Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68 (2005) 800-807
8. Huang L.Y., Wang Y., and Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistant protein. Drug Metab Dispos (2006 (January)) 13
9. Itoda M., Saito Y., Shirao K., Minami H., Ohtsu A., Yoshida T., et al. Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotecan. Drug Metab Pharmacokinet 18 (2003) 212-217
10. Imai Y., Nakane M., Kage K., Tsukahara S., Ishikawa E., Tsuruo T., et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1 (2002) 611-616
11. Mizuarai S., Aozasa N., and Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109 (2004) 238-246
12. Korenaga Y., Naito K., Okayama N., Hirata H., Suehiro Y., Hamanaka Y., et al. Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int. J. Cancer 117 (2005) 431-434
13. Lee E., Ryan S., Birmingham B., Zalikowski J., March R., Ambrose H., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341
14. Sarkadi B., Ozvegy-Laczka C., Nemet K., and Varadi A. ABCG2-a transporter for all seasons. FEBS Lett 567 (2004) 116-120
15. Iida A., Saito S., Sekine A., Mishima C., Kitamura Y., Kondo K., et al. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 47 (2002) 285-310
16. Zamber C.P., Lamba J.K., Yasuda K., Farnum J., Thummel K., Schuetz J.D., et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 1 (2003) 19-28
17. Honjo Y., Morisaki K., Huff L.M., Robey R.W., Hung J., Dean M., et al. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 6 (2002) 696-702
18. Backstrom G., Taipalensuu J., Melhus H., Brandstrom H., Svensson A.C., Artursson P., et al. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharmacol Sci 5 (2003) 359-364
19. Kage K., Tsukahara S., Sugiyama T., Asada S., Ishikawa E., Tsuruo T., et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 97 (2002) 626-630
20. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Schneck D.W., and Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58 (2002) 527-531